论文部分内容阅读
资料来源:www.medscape.com发布日期:2010.5.25发表于New England Journal of Medicine 2010年5月14日的一篇文章报道:Cancer Leukemia Group B(CALGB)49907试验的结果显示:老年早期乳腺癌患者接受标准辅助化疗的疗效显著优于卡培他滨辅助化疗。标准辅助化疗能减半死亡和复发的风险,但它中度至重度不良反应率是卡培他滨的一倍(64%比33%)。“我们的结果支持辅助化疗能提高老年妇女患者的生存率”作者写道,“患者往往比较喜欢口服药
Source: www.medscape.com Publish Date: May 25, 2010 Published in New England Journal of Medicine A May 14, 2010 article reports: Results from the Cancer Leukemia Group B (CALGB) 49907 trial show that early-stage breast cancer in the elderly Patients receiving standard adjuvant chemotherapy were significantly better than capecitabine adjuvant chemotherapy. Standard adjuvant chemotherapy halved the risk of death and relapse, but its rate of moderate to severe adverse events was twice that of capecitabine (64% vs. 33%). ”Our results support adjuvant chemotherapy to improve survival in elderly women,“ the authors write. ”Patients tend to prefer oral medications